Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
How are people who have advanced or metastatic HER2-low breast cancer normally treated?Endocrine therapy: Treatments for HR-positive breast cancer that are designed to block the effects of certain hormones in the body.lung disease and pneumonitis, which are potentially serious medical problems.T-DXd is a treatment option for people with advanced or metastatic HER2-low breast cancer that has been previously treated.
Authors
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/14796694.2024.2434388
- Citations
- 4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- AstraZeneca
- Daiichi-Sankyo
- Daiichi Sankyo Europe